Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
about
A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderlyThe host immune dynamics of pneumococcal colonization: implications for novel vaccine developmentMucosal vaccination against encapsulated respiratory bacteria--new potentials for conjugate vaccines?Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspringCombination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in miceComparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model.Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigenAntibodies to the iron uptake ABC transporter lipoproteins PiaA and PiuA promote opsonophagocytosis of Streptococcus pneumoniae.Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse modelAnalysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.Construction and immunogenicity of recombinant adenovirus vaccines expressing the HMW1, HMW2, or Hia adhesion protein of nontypeable Haemophilus influenzaeHuman nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage.Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidificationCharacterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.Primed peritoneal B lymphocytes are sufficient to transfer protection against Brugia pahangi infection in mice.Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesRole of phosphoinositide 3-kinase-Akt signaling pathway in the age-related cytokine dysregulation in splenic macrophages stimulated via TLR-2 or TLR-4 receptorsIncreased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 alleleIntranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plagueA nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationNovel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cellsImmunization with recombinant Sao protein confers protection against Streptococcus suis infection.Controlled inflammatory responses in the lungs are associated with protection elicited by a pneumococcal surface protein A-based vaccine against a lethal respiratory challenge with Streptococcus pneumoniae in mice.Immunization with Streptococcus suis bacterin plus recombinant Sao protein in sows conveys passive immunity to their pigletsThe Asd(+)-DadB(+) dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccinerIL-22 as an adjuvant enhances the immunogenicity of rGroEL in mice and its protective efficacy against S. Typhi and S. Typhimurium.A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro.Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies.Intranasal vaccines for protection against respiratory and systemic bacterial infections.
P2860
Q28084760-7D92AED7-FAA1-4AD9-B484-B11E968675BCQ28084920-034BC48C-F6BF-4C38-A21C-F621B8BF6603Q28187952-75832767-BF69-4796-9A63-AD1EDE8FE38BQ28743311-235CD2EB-5773-4749-980A-BD87C53B19F7Q33594345-B126A059-F84C-4B03-A18F-BC42CA8322F9Q33724436-0CCB6D11-86B7-4F8F-A6EE-4F54A6DD3AAFQ33725192-6C55CBF3-C87C-437D-B8A3-F6F628A30018Q33798317-CE58FA14-3CFC-415C-8308-24513643CC50Q33899407-6AAAC6B7-58D6-496F-8A9E-852EE4E1D017Q33921859-A6ABBDB6-1B79-4B22-A259-31B10655E485Q34033151-F2782F29-8BC4-4480-A02A-470597AA24F4Q34033275-29DCB334-5EB1-4BFC-847C-BDC65AC86E33Q34130636-2C3C7E55-3931-4E28-908B-8C833E4EEE2FQ34189901-6D5F7C10-23A1-4F1C-835C-9E22DAE1AD0FQ34229627-5F8FC217-7E5C-49A1-9A2F-5BD02FDD3D30Q34579554-03FDA5A4-3D0D-4C76-B16F-10DE1DF8E668Q34637890-B08EE2FE-B3D1-4C47-BC93-400EC2173036Q34714972-BB576D57-2B2D-428B-9AC8-D5F863EC0231Q35036583-1F062290-72A8-441F-A670-53CBCEB46E3EQ35143128-8891F023-9E51-4E68-8BC1-A13641EFE6F3Q35162960-698BC64B-9E14-4D60-B203-DB96B4047E68Q35165637-371893F4-63DE-4596-A2D6-C62D4B0A1E79Q35220270-A0E10C17-18FB-4383-A09E-96923C9BDB46Q35530270-DC63EAAD-C6FE-4539-A461-70CE235FD429Q35543174-7C73E2FA-E455-4E57-BC4C-C144530FFD2EQ35665351-5ED1F635-6BA9-4F4A-9D9C-1910D3AC324FQ35689196-76CE0D5E-FA2E-414C-847D-D16D8B26BC09Q35805480-6AF92458-6A3E-4B84-B280-61F35A9673F5Q35828850-BB0C7E00-2869-4554-BFED-602641ABE65EQ36097153-1BADD766-4797-4457-B621-76AC06B235F1Q36191618-0D8B2D56-7876-4E94-AF09-E299531DC4EDQ36243148-43EEB0FA-B655-44F7-B2EC-3AC5222C7E4EQ36277335-706E9F4E-6593-4E3E-8667-0807B7509323Q36302839-17DF5C8D-D187-47D1-A36D-F99BDEA16BB8Q36306944-9F779A7F-EB87-41F2-8A6C-8E641BBE2E88Q36313904-5AFF2A92-DCCE-431C-B428-C831D6CCAAA4Q36314065-C6E39D02-B012-4A83-9FB0-2E6297BAF406Q36362263-EFBEA112-65C6-453F-994E-18E120FBFB68Q36558990-F8F03C0B-6370-4ED7-B613-7FDBF3D4AF45Q36837156-D1BD20E8-8040-4494-A969-DE81A4027061
P2860
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@ast
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@en
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@nl
type
label
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@ast
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@en
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@nl
prefLabel
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@ast
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@en
Intranasal vaccination with pn ...... tococcus pneumoniae infection.
@nl
P2093
P2860
P1476
Intranasal vaccination with pn ...... ptococcus pneumoniae infection
@en
P2093
B P Arulanandam
D E Briles
S Hollingshead
P2860
P304
P356
10.1128/IAI.69.11.6718-6724.2001
P407
P577
2001-11-01T00:00:00Z